Like type tumors (431 of 487 unique genes matched). We have used two different methods to classify the tumors: two-dimensional hierarchical cluster analysis and nearest centroid classification. We have compared the reproducibility by both methods and we have analyzed clinical outcome (distant metastasis-free probability and overall survival) of these 295 patients based for the different classes. The median follow-up is 6.7 years for all patients and 7.8 years for patients alive. Results Based on hierarchical clustering, the basal subgroup can be easily recognized; the ErbB2 group is reasonably well defined and the luminal A and luminal B groups form a large cluster, with subclusters that have more luminal A or luminal B patients. For the nearest centroid classification we used a correlation threshold of 0.1 to classify patients. One hundred and nine (37 ) patients did not have a correlation of more than 0.1 to one of the five centroids (`unclassifiable’). Forty-five (15.25 ) patients were PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/27193610 assigned to the basal group, Vamorolone 39 (13.2 ) ErbB2, 47 (16 ) luminal A, 45 (15.25 ) luminal B and 10 (3.3 ) normal-breast like. The relatively large group of PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28455751 patients that could not be assigned to one of the classes was further analyzed. These tumors appear to represent a relatively homogeneous group that differs from those that can be classified. The ER receptor is positive in 106/109 (120/188 classifiable patients: two-sided Fisher’s exact P < 1 ?10?) and 80 of the tumors are histological grade I or grade II (47 for classifiable patients; P < 1 ?10?). Not surprisingly, the 10-year overall survival is higher in these patients as well (80 vs 64 ; log-rank: 0.0005). Using predicting analysis of micro-arrays , the unclassifiable `class' could be predicted using 200 genes with an accuracy of 90 (cross-validation results). The 10-year metastasis-free probability and overall survival for the subgroups are: basal, 54 and 46 ; erbB2, 55 and 56 ; luminal A, 70 and 83 ; luminal B, 56 and 63 ; and normal-breast like, 67 and 90 (overall P value: metastasis-free probability, 0.15 and overall survival, 0.001). Conclusion In this series of consecutively treated breast cancer patients, the molecular portraits identify patients that differ with respect to prognosis. The relatively high proportion of unclassifiable patients can possibly be explained by both the cross-platform matching, the difference in clinical stage (locally advanced in the original series versus early stage in our patients), and the fact that the original classification was derived from a relatively small series of tumors. TheP4.25 Cell differentiation and dominant signaling pathway signatures in the molecular classification of human breast cancer cell linesCA Wilson, J Dering, G Bernardo, HM Rong, C Ginther, R Ferdman, AM Cook, R Finn, DJ Slamon David Geffen School of Medicine at UCLA, Los Angeles, California, USA Breast Cancer Research 2005, 7(Suppl 2):P4.25 (DOI 10.1186/bcr1155) Background Differentiation markers characteristic of multiple cell types in the mammary gland have emerged as a dominant feature in gene expression profiles that segregate primary human breast cancers. Immunohistochemical and mRNA expression profiling studies of large breast cancer cohorts have reproducibly identified a subset of tumors ( 15 ) that express markers characteristic of the basal layer of the mammary gland. This is in contrast to the many human breast cancers that uniformly express luminal markers such.
Sorry, there was no activity found. Please try a different filter.